Monday, 4 April 2022
Friday, 1 April 2022
Investor Ideas #Potcasts 629, #Cannabis News and #Stocks on the Move- (CSE: $AUSA.C), (TSXV: $MUSH.V) (TSX: $WEED.TO) (NASDAQ: $CGC)
Investor Ideas #Potcasts
629, #Cannabis News and #Stocks on the Move- (CSE: $AUSA.C), (TSXV: $MUSH.V)
(TSX: $WEED.TO) (NASDAQ: $CGC)
Delta, Kelowna, BC, April 1, 2022 (Investorideas.com Newswire), investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its potcast site release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2022/040122-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2022/cannabis-potcasts/04011AUSA-MUSH-WEED-CGC.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
In today’s podcast
we look at a few private and public company announcements.
AUDACIOUS
(Astralis Capital Inc.) (CSE:AUSA) and Thai-based partner Golden
Triangle Health have partnered to open the first Herbidus Medical Center
in Bangkok, which is also the first medical cannabis clinic in Southeast Asia
supported by a U.S. Multi-State Operator (MSO).
Herbidus is among the first clinics
in Asia that can prescribe cannabis for medical treatments in compliance with
the law. It uses medicine approved by the Government Pharmaceutical
Organization and is staffed by doctors that follow global standards for use of
cannabis in patient treatment.
"Interest in medical cannabis
is expanding rapidly in Thailand," said Terry Booth, Chief Executive
Officer at AUDACIOUS. "With the opening of the Herbidus Medical Center, we
are looking forward to bringing AUDACIOUS' cannabis expertise and seasoned
corporate leadership to the Thai cannabis market. This is one of several
initiatives that we are embarking on with Golden Triangle Health, which along
with its parent company enjoys robust distribution channels across Thailand, as
well as nimble and powerful white label capabilities for cannabis product
manufacturing."
Mr. Booth continued, "GTH will
also receive support from our Chief Science Officer, Dr. Jason Dyck, and will
be able to utilize his knowledge and experience. This provides Herbidus with
access to one of the global leaders in medical cannabis science, resulting in
Herbidus patients receiving the highest standards of care in the industry. This
will leverage the years of research we have performed in Canada and other
countries, including Dr. Dyck's studies on one of the world's largest databases
of medical cannabis users to identify the primary reasons for medical cannabis
authorization and the health outcomes of these patients."
As Thailand begins to more
aggressively expand opportunities for legal cannabis businesses, AUDACIOUS and
Golden Triangle Health are poised to serve the nation of 70 million people with
cannabis services and products grounded in years of successful and professional
cannabis pursuits in North America.
Itself a spin off from Thai public
company NR Instant Produce PCL with market cap close to $400M, GTH is well
positioned to grow rapidly in the nascent Thai market. Following a soft launch,
Herbidus has already seen close to 800 patients, showing the pent-up demand in
Thailand for medical cannabis related services. Dr. Jason Dyck, CSO at
AUDACIOUS, commented, "Leveraging the knowledge gained from years of
studying one of the world's largest databases of medical cannabis users, we
have made significant advances in understanding the medical conditions that
patients are seeking cannabis treatment for as well as studying the health
outcomes of these patients. The results of these studies will now become an
integral part of the knowledge base of the practitioners at our Herbidus
clinics to help our patients."
Golden Triangle co-founder Tom
Kruesopon said, "Golden Triangle Health already has strong brand equity in
Thailand and across Asia. Our partnership with AUDACIOUS to open Herbidus helps
propel us even further," "We believe that together, we can be one of
the most important players in the Asian cannabis market, following our joint
launch in the Asian CBD market earlier this year."
Added AUDACIOUS Chief Operating
Officer Duke Fu: "We believe the nascent cannabis market in Asia offers
thrilling new and massive addressable market for AUDACIOUS. Given Golden
Triangle Health's extensive and positive track record with distribution,
cannabis and hemp manufacturing and healthcare in Thailand, we know this
partnership is ideal for showcasing the true medical and economic benefits of
cannabis."
The
Good Shroom Co Inc. (TSXV : MUSH), discussed their financial & operational
highlights from Q2-2022 and announced the engagement of Paradox Public
Relations Inc.
● The
Company recorded $363,229 in sales revenue. 8.5 X growth from Q1.
● The
majority of this revenue was derived from the launch of its hash in Quebec and
the rest from its functional mushroom beverages.
● Gross
profit margins were of $129,826 compared to $2,526 in Q1.
● Operating
loss was of $241,148 compared to $371,865 in Q1.
MUSH,
through its licensed subsidiary Teonan Biomedical Inc. (the
"Subsidiary"), operates 2 cannabis brands; Nordique Royale™ and
Velada™.
● Nordique
Royale™ launched during Q2 while Velada launched in Q3 in both Quebec and
Ontario.
● In
Quebec, according to https://quebec.weedcrawler.ca/best_sellers,
5/10 best selling infusions are Velada™ products.
MUSH
also operates Teonan™ functional beverages sold across north America.
● Teonan™
was accepted into the distribution networks of the two largest distributors in
the USA, United Natural Foods and Kehe.
● The
Company will be submitting its products to a variety of key retailers during
the course of 2022, including Wholefoods, Albertsons Safeway, Wegmans along
with a large number of regional players across the USA.
● Its
products are now for sale in all Central Market locations in the USA.
The
Company's CEO Eric Ronsse stated "We are pleased with the results of this
quarter where we launched a new cannabis brand which continues to grow. We've
analysed the sales data of our top performing products, identified key product
attributes and have applied them to a variety of new hash based products which
will be submitted for approval in Quebec and Ontario."
Canopy Growth
Corporation (TSX: WEED) (NASDAQ: CGC), a world-leading diversified
cannabis, hemp, and cannabis device company, announced the appointment of Judy Hong and
Jonathan Di Tosto to its Executive Management Team, along with the creation of
four new strategic roles within its Senior Leadership Team.
Effective
immediately, Judy Hong has been appointed as the Company's Chief Financial
Officer. With a proven financial and capital markets background built through
more than 20 years of experience at Goldman Sachs & Co., Judy joined Canopy
in 2019 as the Vice President of Investor Relations. Since arriving, Judy's
deep knowledge of the consumer-packaged goods sector has helped shape Canopy's
engagement with the financial community, as well as the Company's overall
commercial strategy.
The
Company is also pleased to welcome Jonathan Di Tosto to the Executive
Management Team as the Company's new Chief Operations Officer (COO). Jonathan
assumes the role of COO from Andrew MacCorquodale, who is building upon his
five years of dedication to Canopy by transitioning into a strategic advisory
role. Jonathan joined Canopy in May 2021 as Vice President, Supply Chain, where
he has focused on optimizing Canopy's global supply chain organization. Prior
to Canopy, Jonathan spent 16 years with George Weston Limited, most recently as
VP, Planning & Logistics, where he was accountable for the end-to-end
supply chain strategy, process, and execution throughout Canada and the U.S.
"As
Canopy evolves, so does our leadership team and I'm pleased to welcome both
Judy and Jonathan who have demonstrated their capabilities as leaders to drive
our business forward," said David Klein, CEO, Canopy. "As we enter
our new fiscal year and continue our focus on accelerating growth and advancing
on our path to profitability, I feel strongly that we have the right team and
strategy to realize our important ambitions for the benefit of our customers,
team members, and shareholders.''
The
new executive leaders join the Company at a pivotal time, as Canopy enters
Fiscal Year '23 on Friday, April 1st with a focus on continued discipline and
execution against its strategic priorities, including further expanding
Canopy's premium flower portfolio and growing overall premium share in Canada,
scaling the Company's high-impact global brands like BioSteel and Storz and
Bickel, and continuing to develop Canopy's U.S. THC ecosystem pre- and
post-permissibility.
To
support the continued advancement of Canopy's U.S. strategy, the Company has
created four new strategic roles within the Senior Leadership Team. These roles
will be led by seasoned executives who previously held leadership roles at
Constellation Brands and bring with them a breadth of experience, perspective,
and capabilities to help Canopy achieve its business goals in the U.S. cannabis
market in four focused areas: commercial sales, marketing, operations, and
strategic alliances.
"These
roles were developed to leverage Constellation's well-established understanding
of the U.S. market, established commercial relationships, and extensive
operational capabilities," said Klein. "Accessing Constellation's
world-class in-market expertise will allow Canopy to strengthen our competitive
positioning as we continue to build a foundation for long-term success in the
U.S. market."
MAPS Public Benefit
Corporation (MAPS PBC) announced that Michael Mullette, an
experienced drug development and commercialization expert, has joined its
senior leadership team as Chief Operating Officer. Mullette most recently
served as the Vice President and Managing Director of North America for
Moderna, where he oversaw commercialization of the company’s COVID-19 vaccine
during the height of the pandemic.
Mike
is a highly talented, effective, and mission-driven leader who has repeatedly
built teams and organizations that succeed in the face of big and novel
challenges, most recently in his work at Moderna. He brings to MAPS PBC a
wealth of experience in drug development, expertise in drug commercialization,
and a global perspective. With Mike, MAPS PBC is taking another major step in
building a world-class pharmaceutical organization capable of meeting the
enormous need for novel treatments for PTSD and other mental health conditions.
I’m thrilled to expand our team with another experienced partner who shares our
values.
Amy
Emerson, CEO, MAPS PBC
Mullette
joins MAPS PBC after more than 20 years in the pharmaceutical industry. Prior
to his work at Moderna, Mullette developed broad pharmaceutical expertise with
Sanofi in a variety of management roles in the U.S., Australia, France, Japan,
and Canada. He holds a B.S. in Marketing from Villanova University, and an
M.B.A. from Lehigh University.
I
am extremely excited to join MAPS PBC as COO at a critical time of growth for
the organization. Millions of people living with PTSD today need more effective
treatment options, and MAPS PBC is breaking ground with their innovative
approach. I look forward to working with the team to bring MDMA-assisted
therapy and other potential FDA-approved treatments in our pipeline to help
those in need.
Michael
Mullette, COO, MAPS PBC
Mullette’s
primary responsibilities will include:
●
Developing the organization’s long-term
vision and strategy alongside the CEO and Board.
●
Ensuring the company operates effectively
and efficiently across all domains.
●
Achieving a successful first-in-class
commercial launch in the United States.
●
Helping to ensure a high-performing portfolio
and psychedelic medicine pipeline.
●
Developing and executing a strategy for
global expansion and global commercialization of MDMA-assisted therapy.
The
Multidisciplinary Association for Psychedelic Studies and its wholly-owned
subsidiary MAPS PBC have further invested in team members to build the
organization and company:
●
Fede Menapace has been named MAPS’ Chief
Strategy Officer. For the past two years, Fede has served as MAPS’ Director of
Strategy, focusing on organizational growth, financing strategy, and pharma
business development. As CSO, the scope of his role will grow to include the
development of additional revenue-generating initiatives and MAPS’ global
humanitarian efforts to bring psychedelic healing to the countries and
populations most in need.
●
Steven Huang has joined MAPS as Justice,
Equity, Diversity and Inclusion Officer (JEDI), reporting to the Deputy
Director. Steven will guide the JEDI Council, a cross-functional team of
employees across MAPS and MAPS PBC that guides internal policies and the Health
Equity initiative.
●
Debra (Deb) De Angelo, Ph.D., has joined
MAPS PBC as Head of Medical Affairs. Deb was most recently Senior Director of
Medical Affairs at Kaléo and formerly Head of Medical Strategy at Indivior. She
will lead the company’s engagement with the medical community through
publications, conferences, real-world evidence generation and other means.
●
Dawn Lundin, M.S., has joined MAPS PBC as
Head of Global Quality Management Systems. Most recently Director of Compliance
at the University of Pennsylvania’s Perelman School of Medicine, Dawn
previously held senior Quality Assurance roles over the course of two decades
at Merck. Dawn remains a faculty member at Penn directing the QA course of
study for the ITMAT Masters program. She will oversee the quality systems in
support of clinical development activities, ensuring MAPS PBC continues to
follow best practice standards
●
Theresa Gorenc, M.P.H., has joined MAPS PBC
as Head of Market Access. Theresa most recently led market access analytics
teams at AbbVie, where she contributed to the success of over 30 different
medicines. Theresa is responsible for securing coverage and reimbursement for
MAPS PBC’s therapeutics and ensuring accessibility for patients.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and that this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment.
To
hear more Investorideas.com podcasts visit:
https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google
Podcasts and most audio platforms available.
About Investorideas.com - News that Inspires Big Investing
Ideas
Investorideas.com
publishes breaking stock news, third party stock research , guest posts and
original articles and podcasts in
leading stock sectors. Learn about
investing in stocks and get investor
ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy, gaming and more. Investor Idea’s original branded content includes
podcasts and columns : Crypto Corner , Play
by Play sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast ,
Cleantech
and Climate Change , Exploring
Mining , Betting
on Gaming Stocks Podcast and the AI
Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Thursday, 31 March 2022
Wednesday, 30 March 2022
Subscribe to:
Posts (Atom)
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...